AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04495166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Psychotherapy
Description: Brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation (BA). Participants will be guided by psychotherapists to plan, schedule, and engage in positively reinforcing activities, and will be aided to develop problem-solving strategies for circumventing barriers to completing scheduled activities. Implementation of these techniques will be conducted with the aid of the Motherly 1.0 for participants in the experimental arm; for participants in the control arm, BA will be implemented without the aid of Motherly 1.0. Throughout the four sessions, psychotherapists will monitor participants' adherence, answering questions about the strategies and providing support for solving problems or CBT techniques, such as cognitive restructuring, relaxation techniques, sleep hygiene, stress and anxiety management, among other evidence-based techniques might be used if appropriate to the case.
Study NCT04495166 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational app
Description: A simplified version of the Motherly 1.0 app consisting of psychoeducational content about various aspects of pregnancy, maternal physical and mental health, and child development. Active intervention functionalities, such as behavioral activation, activity scheduling, sleep hygiene, among others, are NOT present in this simplified version of the app.
Study NCT04609436 — intervention group
Intervention type: DEVICE
Intervention: Cardiac monitoring with the wireless device SmartCardia
Description: Monitoring of arrhythmia with a wireless device (SmartCardia)
Study NCT00859495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.
Study NCT00859495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Platinum-based antineoplastic
Study NCT00859495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Folate Analog Metabolic Inhibitor
Study NCT00859495 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard procedure given 3 weeks after last dose of chemotherapy
Study NCT00854776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole
Description: 30 mg once daily
Study NCT00854776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aluminum hydroxide 334 mg and Mg hydroxide 166 mg
Description: 1 tablet once daily
Study NCT03688841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridged V.A.C.® with compression therapy
Description: Patients randomised to receive Bridge VAC with compression dressings will be managed using ActiV.A.C. Therapy unit, with a continuous pressure of 125mmHg. A V.A.C.® Granufoam™ Bridge Dressing will be used instead of the tube connector. A Coban™ Lite compression dressing will be placed over the VAC dressing. The Bridge connector of the VAC will be used to tunnel underneath the Coban™ Lite till the upper edge of the dressing.
Study NCT03688841 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Compression Therapy
Description: Patients randomised to receive compression dressings will be managed using Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings. Under the supervision of the investigating clinician, the dressings will be applied by a wound care specialist nurse and changed once to three times per week (depending on amount of exudate), until full ulcer healing or up to 12 weeks.
Study NCT01354964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT01354964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00887822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
Study NCT00887822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to bevacizumab on Day 1 of every 3-week cycle
Study NCT00887822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle
Study NCT00887822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle
Study NCT00887822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
Study NCT00887822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
Study NCT02592980 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic anticoagulation
Description: The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
Study NCT02592980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional anticoagulation
Description: The physician will adjust the dose according to current INR value based on guidelines.
Study NCT02473029 — intervention group
Intervention type: RADIATION
Intervention: Vascular tomodensitometry
Study NCT02473029 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance angiography
Study NCT02473029 — intervention group
Intervention type: OTHER
Intervention: Vascular ultrasonography
Study NCT02473029 — intervention group
Intervention type: OTHER
Intervention: Retinal angiography
Study NCT02473029 — intervention group
Intervention type: OTHER
Intervention: Retinal optical coherence tomography
Study NCT01219959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dianeal
Description: Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
Study NCT01219959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dianeal, Extraneal, Nutrineal
Description: Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
Study NCT00262457 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implanted gluteal electrical stimulation system
Description: Implanted electrical stimulation system incorporating BION microstimulators
Study NCT00676468 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Montelukast + Fish Oil Placebo
Description: Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
Study NCT00676468 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Fish Oil + Montelukast Placebo
Description: 10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
Study NCT00676468 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Montelukast + Active Fish Oil
Description: 1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
Study NCT03204331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 40-mg tablet administered orally once daily.
Study NCT03204331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
Study NCT03204331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
Study NCT03204331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
Study NCT03204331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Relugolix placebo
Description: Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
Study NCT00984958 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bulkamid
Description: injection of Bulkamid in the urethra
Study NCT00984958 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bulkamid expectation
Description: expectance
Study NCT05950399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo resting echocardiography
Study NCT05950399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT05950399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05950399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress Echocardiography
Description: Undergo stress echocardiography
Study NCT05950399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress Echocardiography
Description: Undergo stress echocardiography
Study NCT02189837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered by mouth
Study NCT02189837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered by mouth
Study NCT03575741 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Balance Tests
Description: Following balance exercises will be performed by the participants:~1. Bipedal, hip wide stand, eyes open and hands on hips, 60sec~2. Bipedal, hip wide stand, eyes closed, hands on hips, 30sec~3. Tandem-stand, eyes open, hands on hips, 60sec (front foot chosen by participant)~4. Tandem-stand, eyes closed, hands on hips, 30sec (same front foot)~5. One-leg-stand, eyes open, hands on hips, 30sec (randomized supporting leg)~6. One-leg-stand, eyes open, hands on hips, 30sec (other leg)~7. Bipedal, hip wide stand, eyes open, hands on hips, counting backwards in steps of two (367 - 365 - 363 - ...), 60sec~The rest between the trials will last for at least 30sec, but can be extended by the participants as long as they want. The overall measurement will not exceed 30 minutes.
Study NCT02189837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT02189837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT02189837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Atorvastatin
Description: Administered by mouth
Study NCT02189837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Atorvastatin
Description: Administered by mouth
Study NCT01597778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical Bone Marrow Transplant
Description: The conditioning regimen consists of:~Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1~The GVHD prophylaxis regimen consists of:~Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35
Study NCT01597778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Umbilical Cord Blood Transplant
Description: The preparative regimen consists of:~Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.~The GVHD prophylaxis regimen consists of:~Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.~Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35
Study NCT02419781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rescue endovascular therapy
Description: endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy
Study NCT02419781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No endovascular therapy
Study NCT01624025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks
Description: Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
Study NCT01624025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks
Description: Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
Study NCT02214992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Ramipril
Description: Fixed dose combination tablet
Study NCT02214992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT02214992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril capsule
Study NCT02214992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril tablet
Study NCT01088958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient powders (Sprinkles)
Description: Sprinkles were developed in 1996 by Stanley Zlotkin's research group at the Hospital for Sick Children, University of Toronto as a novel approach for delivering iron and other micronutrients. They come in 1g sachets of dry powder that is then added to any home-prepared semi-solid food, intended for daily consumption by children aged 6-59 months. Formulation includes:~Iron (Ferrous fumarate) 12.5 mg, Folic acid 150 µg, Vitamin A 375 µg, Vitamin C 35 mg, Zinc 5 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Vitamin B12 0.9 µg, Vitamin D3 5 µg, Vitamin E 6.0 mg, Niacin 6.0 mg, Copper 0.6 mg, Iodine 50 µg
Study NCT01434914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: octenisept®
Description: Cutaneous solution
Study NCT01434914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cutaneous use
Study NCT05593744 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This is an observational study so not involved intervention
Study NCT01439581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mapping System
Description: Pressure Sensing coverlet on ICU bed and provides real time feedback to assist in effective patient repositioning
Study NCT01439581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Mapping System
Description: Standard ICU bed with no mapping system
Study NCT02076087 — intervention group
Intervention type: PROCEDURE
Intervention: Liposuction/lipectomy
Description: Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
Study NCT04146012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artegraft® Collagen Vascular Graft™ (Artegraft)
Description: The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
Study NCT01050439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UDAlloSCT
Description: unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
Study NCT01050439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
Study NCT02474277 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 30 sec chair stand test
Description: diagnostic test for functional impairment
Study NCT03507088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoroestradiol (18F)
Description: A FES-PET/(CT) will be performed twice during protocol execution. Patients will be injected with approximately 222 MBq 18F-FES each time.
Study NCT00939211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00939211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03042884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Exercise Tracker Watch
Description: Inpatient Group: Participants receive a wearable exercise tracker watch upon admission to acute inpatient rehabilitation unit. Participant to wear the exercise tracker watch on their wrist for 24 hours a day. Device to be returned within 24 hours before being discharged.~Outpatient Group: Participants receive a wearable exercise tracker watch to wear on their wrist for 24 hours a day for 14 days. Device to be returned at next visit.
Study NCT00727155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjusting to Chronic Conditions Using Education Support and Skills
Description: This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
Study NCT05370105 — intervention group
Intervention type: OTHER
Intervention: blood withdrawal
Description: 10 ml of blood, two 5 ml tubes suitable for serum isolation. Given the nature and objectives of the study, there are no risks and / o inconveniences of particular importance for the patient since the blood samples will be performed according to the common procedure used in all analysis laboratories. At the end of the collection, in the area where the blood sample was taken, a small bruise may form which will disappear in the following hours, in any case during the collection particular attention will be paid to the subjects being treated with antiplatelet and anticoagulants.~The study does not include the execution of interventional treatments or therapies.
Study NCT00767403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Intervention + Stepped Care
Description: Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones.
Study NCT00767403 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Intervention
Description: As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses.
Study NCT00767403 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education Website
Description: Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
Study NCT00748761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Nondrug psychotherapy administered weekly for 12 weeks
Study NCT00748761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Nondrug psychotherapy administered weekly for 12 weeks
Study NCT00748761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Contact waitlist weekly for 12 weeks
Study NCT00795327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra (Poly-L-Lactic Acid Dermal Implant)
Description: Drug Device study
Study NCT00511732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Description: Technosphere Insulin Inhalation Powder
Study NCT00511732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Technosphere Placebo
Description: Technosphere Inhalation Powder
Study NCT04168892 — intervention group
Intervention type: DRUG
Intervention: 150 IU of HMG in patients with age ≤ 35 years
Description: The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.